Open an account

HTG Molecular Diagnostics

HTGMQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About HTGMQ

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. The company is headquartered in Tucson, Arizona and currently employs 53 full-time employees. The company went IPO on 2015-05-06. The firm is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The firm's Gene Expression Panels include HTG Research Use Only (RUO) Panels and HTG EdgeSeq Research Use Only (RUO) Panels, such as the HTG Transcriptome Panel, HTG EdgeSeq miRNA Whole Transcriptome Assay, HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq Precision Immuno-Oncology Panel, HTG EdgeSeq Immune Response Panel, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG EdgeSeq Mouse mRNA Tumor Response Panel, and HTG EdgeSeq DLBCL Cell of Origin Assay. The HTG EdgeSeq system provides gene expression profiling for researchers, laboratory staff, and biomarker leads in discovery, translational medicine, and oncology applications. VERI/O Laboratory Services is a molecular lab providing gene expression profiling results.

Employees
54
Headquarters
Tucson, Arizona
Listed
May 6, 2015
Sector
Health Care
Industry
Health Care Technology
Website
htgmolecular.com

HTGMQ key statistics

Market cap
2
Price-earnings ratio
—
Dividend yield
—
Average volume
1.60K
Volume
82
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

HTG Molecular Diagnostics (HTGMQ) at a glance

HTG Molecular Diagnostics (HTGMQ) last traded at $0.00, with a market cap of 2.

Volume so far is 82 shares, below the average of 1.60K shares a day.

Over the past year HTG Molecular Diagnostics has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

HTG Molecular Diagnostics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY23 it reported -$2.28 per share against an estimate of -$2.00.

HTGMQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 17.3% on average.

  1. Q2 FY21: reported -$7.80 per share against an estimate of -$9.49
  2. Q3 FY21: reported -$7.20 per share against an estimate of -$8.22
  3. Q4 FY21: reported -$8.28 per share against an estimate of -$7.25
  4. Q1 FY22: reported -$9.72 per share against an estimate of -$8.84
  5. Q2 FY22: reported -$6.48 per share against an estimate of -$7.48
  6. Q3 FY22: reported -$4.92 per share against an estimate of -$6.61
  7. Q4 FY22: reported -$5.28 per share against an estimate of -$2.48
  8. Q1 FY23: reported -$2.28 per share against an estimate of -$2.00

Similar companies

Companies in the same industry as HTG Molecular Diagnostics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.